ArticleScientific reports2025
GRUATT-AVP: leveraging a novel attention-based gated recurrent unit to advance the accuracy of antiviral peptide prediction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antiviral peptides (AVPs), produced by all living organisms, play a vital role as the first line of immune defense against viral infections. AVPs present a promising path for developing novel antiviral therapies that target diverse viruses, including those resistant to existing drugs. However, identifying AVPs using wet lab methods is often costly and requires significant effort, and existing computational methods still have certain limitations. In this study, a novel attention-based Gated Recurrent Unit framework, named GRUATT-AVP, is proposed for accurate and fast AVPs identification. In GRUATT-AVP, several Natural Language Processing (NLP) based encoding mechanisms, including One-Hot Encoding, Word2Vec, GloVe, FastText, and ProtBert, are adopted to encode the peptide sequences. Sequentially, different embedding dimensions based on the k-mer with fixed lengths (1-6) and pooling were explored, aiming to capture the local context within the sequences. After that, we conducted another experiment to determine the best feature selection technique and integrated the SHAP technique to eliminate noise and less important encoded features, thereby improving the model's generalization performance. Finally, the most informative subset was fed into our developed GRUATT-AVP model to construct the GRUATT-AVP for classification. To understand the contribution of each component in the GRUATT-AVP model, an ablation study was performed, and the outcomes showed that our proposed model outperforms its other variants, establishing the model's stability and efficacy. In terms of AVP prediction results, GRUATT-AVP demonstrated better performance compared to several state-of-the-art classifiers, with an accuracy of 94.8% and an AUC of 0.986, suggesting promising therapeutic potential against viral infections. To ensure wide accessibility and practical usage, the GRUATT-AVP web server is available at https://gruatt-avp.vercel.app/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.